Lipid nanoparticle delivery and cellular entry. Elasomeran (mRNA-1273) is administered by intramuscular injection, where its nucleoside-modified mRNA is encapsulated in a lipid nanoparticle (LNP) formulated to protect the mRNA against degradation, facilitate endosomal escape, and enable targeting to the desired cell type. The ionizable lipid component specific to mRNA-1273 is SM-102, distinct from ALC-0315 used in BNT162b2. After injection, the vaccine triggers a transient localized inflammatory response and recruits monocytes, macrophages, and dendritic cells to the injection site. Although dosing is intramuscular, LNP biodistribution studies show that most reporter signal is detected in the liver and spleen within 6 hours post-injection, indicating systemic trafficking to reticuloendothelial organs. LNP in vivo performance depends additionally on surface remodeling: PEG-lipid desorption is a necessary process for efficacious mRNA delivery to target tissues, illustrating how excipient kinetics govern cytosolic access.

Spike protein expression. Once LNPs are internalized and undergo endosomal escape, cellular uptake and translation of exogenously delivered mRNA begins immediately. The mRNA encodes the full-length SARS-CoV-2 spike (S) protein with two proline substitutions, K986P and V987P, which stabilise the protein in the prefusion conformation. Structurally, these proline substitutions at two consecutive residues in the hinge region between the central helix and heptad repeat 1 of S2 prevent the conformational change into the postfusion state, locking the receptor-binding domain in its native immunogenic form at the cell surface.

Antigen presentation and initial innate signaling. Following translation and post-translational processing, the spike protein is degraded in the cytoplasm into fragments that form complexes with MHC class I molecules, enabling direct CD8⁺ T cell priming. In parallel, antigen–MHC class II complexes presented on the cell surface drive production of antigen-specific CD4⁺ helper T cells that provide B cell help for antibody production. The LNP carrier contributes its own innate stimulus: variation in the ionizable lipid component determines the magnitude of the local immune response, and ionizable lipids within LNPs signal through TLR4 to activate NF-κB and IRF transcriptional programs, providing an intrinsic adjuvant effect independent of the mRNA cargo.

N1-methylpseudouridine substitution and innate immune evasion. A parallel target-independent pathway shapes the balance between antigen yield and interferon suppression. Every uridine in elasomeran's mRNA is replaced by N1-methylpseudouridine (m1Ψ). This modification means that incorporation of Ψ or m1Ψ in mRNA markedly suppresses activation of TLR3, TLR7, and TLR8 and markedly reduces RIG-I responsiveness. For residual double-stranded RNA species, cytosolic sensing proceeds via MAVS: loss of MAVS obliterates IFN induction across all mRNA preparations, while removal of RIG-I results in complete abrogation of IFN signaling, confirming RIG-I as the primary cytosolic dsRNA sensor. By blunting these pathways, m1Ψ substitution simultaneously reduces reactogenicity-driving interferon output and increases translational efficiency, boosting antigen yield per dose.

Adaptive immune cascade. The innate milieu and antigen presentation context drive coordinated T–B cell cooperation in the draining lymph nodes. Nucleoside-modified mRNA-LNP platforms induce high levels of T follicular helper (Tfh) cells and germinal center (GC) B cells, and the resulting Tfh response and high GC B cell and plasma cell numbers are associated with long-lived, high-affinity neutralizing antibodies and durable protection. GC responses strongly correlate with neutralizing antibody production. In humans, S-specific TFH cells peak one week after the second dose and persist at near-constant frequencies for at least six months. CD4⁺ T cell responses are strongly biased toward Th1 cytokines — TNF-α, IL-2, and IFN-γ — with minimal Th2 cytokine expression, a polarization profile associated with effective antiviral immunity and reduced immunopathology risk.

Clinical translation. These molecular and cellular events produce measurable population-level protection. In the phase 3 COVE trial, vaccine efficacy in preventing COVID-19 illness was 93.2%, and efficacy against severe disease was 98.2%, with only 2 cases in the mRNA-1273 group versus 106 in placebo. Antibody correlate analyses show that Day 57 spike IgG, RBD IgG, cID50, and cID80 neutralization titers are each inversely correlated with subsequent COVID-19 risk, with modeled efficacy rising steeply at higher titers. Against variants of concern, all tested VOCs remained susceptible to mRNA-1273-elicited serum neutralization despite 1.2- to 8.4-fold titer reductions relative to D614G. Across studies, both binding and neutralizing antibody levels against spike correlate with the degree of vaccine efficacy, providing a quantitative bridge from antigen design and germinal center biology to real-world clinical outcomes.